Examples of using Dndi in English and their translations into German
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
As a result we were happy to sign an agreement with DNDi.
DNDi is funded by governments, private foundations, and individual donors.
Together with the non-profit Drugs for Neglected Diseases Initiative(DNDi), Bayer is currently developing a new drug that will be able to eliminate adult worms as well.
DNDi develops safe, effective, and- most importantly- affordable drugs for neglected diseases.
Licensing agreements concluded, for example the agreement announced between DNDi and Abbott, ensure patient access to drugs developed from the collaboration in all endemic countries, regardless of income level.
DNDi was founded in 2003 to address a systemic lack of R& D for certain neglected diseases.
We need to build on the experience and progress of the past twenty years and give new impetus to research and development for new health tools to accelerate the elimination of river blindness in targeted countries of Africa', explains Dr Bernard Pécoul,Executive Director of DNDi.
DNDi supports health staff and doctors at several clinical research facilities with treatments and diagnostic tools.
With 400 attendees- key actors in the field of research and development for neglected diseases, including international scientists, product developers, policy-makers, and civil society organizations- explores the scientific aspects of the past decade of innovation for neglecteddiseases carried out by various innovative initiatives, including DNDi.
We are looking forward to joining DNDi in its mission to develop better and adapted treatments for patients with neglected diseases.
Deutsch'The fact that this Nobel Prize has been awarded to parasitologists who devoted their careers to the treatment of diseases that affect poor populations in low- and middle-income countries shows that research and development(R& D) can deliver concrete solutions of great importance to global public health', said Dr Bernard Pécoul,Executive Director of DNDi.
For Bayer the cooperation with the DNDi in the fight against river blindness builds upon a long-standing commitment against neglected tropical diseases.
DNDi operates globally through a number of private and public partnerships in more than 40 countries- including 50 public research centres and 20 pharmaceutical and biotech companies.
The additional licenses are rapidly needed by DNDi, especially for new studies in the Democratic Republic of the Congo(DRC), to add more clinical sites and staff.
DNDi is responsible for preclinical, clinical, and pharmaceutical development, while Sanofi is responsible for the industrial development, registration, and production of the drug at its manufacturing sites.
About the London NTD event The commitments announced by DNDi are a key part of a new, coordinated push by a diverse range of public and private partners to combat 10 Neglected Tropical Diseases(NTDs) by 2020.
DNDi aims to improve the quality of life and health of people suffering from these diseases- by an alternative model for drug development and by ensuring equal access to new and adapted therapies to patients in need.
In addition to the treatments already delivered, DNDi plans to develop at least another five new treatments by 2018, and the SDC's support will be key to attaining this objective.
Pascal Carpentier, DNDi Head of Information Systems and Technologies:„We use PowerFolder to collect microscope videos and photos taken in our hospitals in the Democratic Republic of the Congo, to find possible indications of an infection with the sleeping sickness.
About'Connect to Fight Neglect' As part of its 10th anniversary, DNDi has launched a special advocacy website to give voice and attention to neglected patients and those working to develop and deliver life-saving treatments for them.
DNDi has helped establish three clinical research platforms: Leishmaniasis East Africa Platform(LEAP) in Kenya, Ethiopia, Sudan, and Uganda; the HAT Platform based in the Democratic Republic of Congo(DRC) for sleeping sickness; and the Chagas Clinical Research Platform in Latin America.
Working collaboratively with public and private partners worldwide, DNDi has developed six new treatments for neglected patients, with several new drug candidates in the R& D pipeline, including two for sleeping sickness(fexinidazole, oxaborole/SCYX-7158) and one for Chagas(E1224) in clinical trials.
DNDi, Anacor, SCYNEXIS, and a consortium including Pace University and the Swiss Tropical and Public Health Institute then worked on the series of molecules in pre-clinical studies that led to the development of the compound for which DNDi is filing a dossier for first in man(FIM) studies to enter Phase I clinical trials in Europe.
Celebrating its 10-year anniversary, DNDi and two of its founding partners, Institut Pasteur and MSF, are co-hosting a special scientific conference at Institut Pasteur in Paris, France.
Since its foundation, DNDi has made available six treatments for neglected diseases, including two for malaria, one for sleeping sickness, one for visceral leishmaniasis(VL) in East Africa, a set of treatments for VL in Asia, and a paediatric dosage form of benznidazole for Chagas disease.
Based on its experience, DNDi concludes that its cost of development ranges from EUR 6-20 million for an improved treatment, and EUR 30-40 million for a new chemical entity.
About Drugs for Neglected Diseases initiative(DNDi) DNDi is a not-for-profit research and development organization working to deliver new treatments for neglected diseases, in particular human African trypanosomiasis, leishmaniasis, Chagas disease, malaria, and, with the recent expansion of its portfolio, specific helminth-related infections and pediatric HIV.